ProfileGDS5678 / 1451446_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 93% 94% 94% 94% 92% 93% 93% 94% 93% 93% 93% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.5206195
GSM967853U87-EV human glioblastoma xenograft - Control 27.9224593
GSM967854U87-EV human glioblastoma xenograft - Control 38.050994
GSM967855U87-EV human glioblastoma xenograft - Control 48.2311394
GSM967856U87-EV human glioblastoma xenograft - Control 58.2330394
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.4875692
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.7728393
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.7739393
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.0561894
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8037893
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.7537793
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9474593
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.8485493
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.7459893